What 4DMT does

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company developing genetic medicines through a proprietary directed evolution platform that creates customized adeno-associated virus (AAV) vectors tailored to specific disease applications. The company's core technology differs from competitors in that vectors are invented via iterative directed evolution rather than relying on naturally occurring or minimally modified capsids. Clinical development is concentrated in two therapeutic areas: retinal diseases and pulmonary diseases. The lead clinical candidate, 4D-150, is an intravitreally-administered gene therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) that has demonstrated up to 90% reduction in anti-VEGF injection burden and maintenance of visual acuity at two years in clinical trials. The second clinical candidate, 4D-710, is an inhalable gene therapy designed to deliver functional CFTR genes to lung cells in cystic fibrosis patients who do not adequately respond to existing CFTR modulators (approximately 10% of CF patients).

The company's pipeline is supported by multiple regulatory milestones: 4D-150 in wet AMD has completed Phase 3 enrollment (February 2026), 4D-150 in DME is advancing to Phase 3 following FDA RMAT designation (May 2025), and 4D-710 continues in CF development with CF Foundation support. 4DMT has also expanded beyond its core indications through a partnership with Arbor Biotechnologies to address central nervous system diseases using its directed evolution platform.

4DMT is pre-revenue with no commercialized products and headquarters in Emeryville, California. The revenue model contemplates future product sales upon regulatory approval, supplemented by licensing and partnership economics including upfront payments, development milestones, and royalties. Material partnership deals include the Astellas license (potential value up to $962 million, July 2023), the Otsuka collaboration focused on retinal Phase 3 development (potential value up to $420 million, October 2025), the Arbor Biotechnologies CNS collaboration (January 2023), and ongoing Cystic Fibrosis Foundation investment. The company acquired an eye disease asset from a Fortress Biotech subsidiary in September 2023 to broaden its retinal pipeline. Distribution upon commercialization is expected to flow through specialist healthcare providers (retina specialists, pulmonologists) and/or partnership with larger pharmaceutical companies for specific markets.

Name

4DMT

Legal name

4D Molecular Therapeutics

Website

https://4dmt.com

Company type

Private

Operating status

Operating

Short description

4D Molecular Therapeutics is a clinical-stage biotech using proprietary directed evolution to invent customized AAV gene therapies, with lead candidate 4D-150 in wet AMD and DME Phase 3 trials and 4D-710 for cystic fibrosis pulmonary delivery.

Ownership category

akta.pro rank

Product category

Genetic Medicines

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

Keywords

• Gene therapy development
• AAV vector platform
• Directed evolution biotechnology
• Retinal disease therapeutics
• Cystic fibrosis treatment

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Product Development & Clinical Trials: Pre-revenue clinical-stage company developing genetic medicines. No commercialized products yet. Revenue will come from product sales upon regulatory approval.
2. Licensing & Partnership Deals: Biopharmaceutical companies license 4DMT's proprietary vectors and technologies for specific applications. Examples include Astellas deal (up to $962M potential) and Otsuka deal (up to $420M potential), generating upfront payments, development milestones, and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

4DMT is a clinical-stage biotechnology company that develops customized genetic medicines using a proprietary directed evolution platform for engineering adeno-associated virus (AAV) vectors. The company is advancing clinical-stage gene therapy candidates including 4D-150 (intravitreally administered for wet AMD and diabetic macular edema) and 4D-710 (inhalable for cystic fibrosis), generating revenue through biopharmaceutical licensing deals and development partnerships.

Product overview

4DMT is a clinical-stage genetic medicine company developing a portfolio of proprietary gene therapy product candidates using its evolved AAV vector platform. The company's lead products include 4D-150 (intravitreally-administered gene therapy for wet AMD and DME showing 90% reduction in anti-VEGF injection burden) and 4D-710 (inhalable gene therapy for cystic fibrosis). The 4D Vector Platform leverages directed evolution to create customized vectors optimized for specific diseases, primarily focused in retina and pulmonology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• 4D-150 A proprietary intravitreally-administered gene therapy product candidate for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Uses customized AAV vectors to deliver anti-VEGF expression, demonstrating 90% reduction in treatment burden versus standard-of-care anti-VEGF injections in clinical trials. Targets patients with retinal vascular diseases who currently require frequent eye injections.
• 4D-710 An inhalable gene therapy candidate for cystic fibrosis, designed to deliver functional CFTR genes to lung cells using aerosolized AAV vectors. Targets CF patients who do not respond to existing CFTR modulators (approximately 10% of CF patient population). Delivered via aerosol inhalation to restore CFTR production in the lungs.
• 4D Vector Platform A proprietary genetic medicine engine using directed evolution to invent and develop customized AAV (adeno-associated virus) vectors optimized for specific disease applications. The platform is licensed to biopharmaceutical partners (including Astellas and Otsuka) for development of gene therapies in specific therapeutic areas, generating upfront payments, development milestones, and royalties.

Quantifiable outcome

• 90% reduction in wet AMD treatment burden with intravitreally administered 4D-150
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered major and core.

• OtsukamajorStrategic or Co-development Partner · 1 October 2025Otsuka partnership with 4DMT focused on retinal gene therapy Phase 3 plans. Potential deal value of up to $420 million, with cash aimed at supporting 4DMT's retinal gene therapy Phase 3 development programs.
• Astellas PharmamajorOEM/ Whitelabel/ Licensing Partner · 1 July 2023Astellas licensed 4DMT's AAV viral vector for rare eye disease gene therapy development. Potential total deal value up to $962 million including upfront, development, and commercial milestones, plus royalties.
• Arbor BiotechnologiescoreStrategic or Co-development Partner · 1 January 2023Partnership to develop genetic medicines for CNS diseases. Combines 4DMT's directed evolution vector platform with Arbor's genomic medicine capabilities for central nervous system applications.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4DMT